Thrombocytopenia, unspecified. D69.6 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM D69.6 became effective on October 1, 2019.
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism D69.59 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D69.59 became effective on October 1, 2021.
A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition. heparin induced thrombocytopenia (HIT) ( ICD-10-CM Diagnosis Code D75.82 transient thrombocytopenia of newborn ( ICD-10-CM Diagnosis Code P61.0
D69.5 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. The 2022 edition of ICD-10-CM D69.5 became effective on October 1, 2021.
reactive thrombocytosis (D75.838)secondary thrombocytosis (D75.838)thrombocythemia NOS (D75.839)thrombocytosis NOS (D75.839)
Thrombocytopenia, unspecified D69. 6 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D69. 6 became effective on October 1, 2021.
The ITP Syndrome ITP is an autoimmune bleeding disorder caused by various etiologies, which is characterized by increased platelet destruction and impaired production, resulting in a decreased platelet count. Primary ITP is idiopathic, whereas secondary ITP is linked to an underlying condition (1).
Other secondary thrombocytopenia The 2022 edition of ICD-10-CM D69. 59 became effective on October 1, 2021. This is the American ICD-10-CM version of D69. 59 - other international versions of ICD-10 D69.
ICD-10-CM Code for Thrombocytopenia, unspecified D69. 6.
Z86. 2 - Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | ICD-10-CM.
Secondary thrombocytopenia is similar to primary or idiopathic thrombocytopenia (ITP) in that it is characterized by reduced platelet production or increased platelet destruction resulting in platelet levels<60,000/microL.
Types of thrombocytopeniaidiopathic (or immune) thrombocytopenic purpura (ITP)thrombotic thrombocytopenic purpura (TTP)haemolytic uraemic syndrome (HUS).
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of blood cells called platelets, a situation which is referred to as thrombocytopenia.
Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events.
ICD-10-CM Code for Antineoplastic chemotherapy induced pancytopenia D61. 810.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
Clinical Information. A condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.
A decrease in the number of platelets in the blood that may result in easy bruising and excessive bleeding from wound s or bleeding in mucous membranes and other tissues. A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen. A subnormal level of blood platelets.
The ICD code D695 is used to code Heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count), due to the administration of various forms of heparin, an anticoagulant.
HIT predisposes to thrombosis, the abnormal formation of blood clots inside a blood vessel, and when thrombosis is identified the condition is called heparin-induced thrombocytopenia and thrombosis (HITT). HIT is caused by the formation of abnormal antibodies that activate platelets.